
## Mario I Fernandez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/681448/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-Term Oncological and Functional Outcomes After Robot-Assisted Partial Nephrectomy for Clinically Localized Renal Cell Carcinoma. Annals of Surgical Oncology, 2022, 29, 2484-2494.	0.7	3
2	What Is the Significance of Variant Histology in Urothelial Carcinoma?. European Urology Focus, 2020, 6, 653-663.	1.6	126
3	Impact of arsenic exposure on clinicopathological characteristics of bladder cancer: A comparative study between patients from an arsenic-exposed region and nonexposed reference sites. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 40.e1-40.e7.	0.8	7
4	Postadmixture Selection on Chileans Targets Haplotype Involved in Pigmentation, Thermogenesis and Immune Defense against Pathogens. Genome Biology and Evolution, 2020, 12, 1459-1470.	1.1	11
5	Arsenic exposure is associated with significant upper tract urothelial carcinoma health care needs and elevated mortality rates. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 638.e7-638.e13.	0.8	4
6	Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer. World Journal of Urology, 2019, 37, 3-13.	1.2	42
7	Adaptation to Extreme Environments in an Admixed Human Population from the Atacama Desert. Genome Biology and Evolution, 2019, 11, 2468-2479.	1.1	13
8	Prevalence of Chlamydia Trachomatis , Neisseria Gonorrhoeae , and Trichomonas Vaginalis Infection in Chilean Adolescents and Young Adults. Journal of Pediatric and Adolescent Gynecology, 2018, 31, 411-415.	0.3	18
9	Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU International, 2017, 119, 684-691.	1.3	36
10	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. Journal of Urology, 2017, 197, 287-295.	0.2	43
11	Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 379-387.	1.2	260
12	Clinical Outcomes of cT1 Micropapillary Bladder Cancer. Journal of Urology, 2015, 193, 1129-1134.	0.2	101
13	Immediate postoperative morbidity in patients with indwelling double-J stent versus overnight-externalized ureteral catheter after tubeless percutaneous nephrolithotomy: a prospective, randomized study. Urolithiasis, 2013, 41, 253-256.	1.2	5
14	Â-H2AX level in peripheral blood lymphocytes as a risk predictor for bladder cancer. Carcinogenesis, 2013, 34, 2543-2547.	1.3	22
15	Long-Term Impact of Arsenic in Drinking Water on Bladder Cancer Health Care and Mortality Rates 20 Years After End of Exposure. Journal of Urology, 2012, 187, 856-861.	0.2	63
16	The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 821-824.	0.8	33
17	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 252-258.	0.8	88
18	Additive antitumoral effect of interleukin-12 gene therapy and chemotherapy in the treatment of urothelial bladder cancer in vitro and in vivo. International Urology and Nephrology, 2011, 43, 721-727.	0.6	3

Mario I Fernandez

#	Article	IF	CITATIONS
19	Postoperative morbidity of tubeless versus conventional percutaneous nephrolithotomy: a prospective comparative study. Urological Research, 2011, 39, 477-481.	1.5	22
20	Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. European Urology, 2010, 57, 1072-1079.	0.9	155
21	Tumour Necrosis Is an Indicator of Aggressive Biology in Patients with Urothelial Carcinoma of the Upper Urinary Tract. European Urology, 2010, 57, 575-581.	0.9	154
22	Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. Journal of Clinical Oncology, 2009, 27, 612-618.	0.8	260
23	Topical Chemotherapy in Human Urothelial Carcinoma Explants: A Novel Translational Tool for Preclinical Evaluation of Experimental Intravesical Therapies. European Urology, 2009, 56, 504-511.	0.9	7
24	Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. European Urology, 2009, 56, 1-9.	0.9	161
25	The Extent of Lymphadenectomy Seems to Be Associated with Better Survival in Patients with Nonmetastatic Upper-Tract Urothelial Carcinoma: How Many Lymph Nodes Should Be Removed?. European Urology, 2009, 56, 512-519.	0.9	143
26	Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymphâ€node density. BJU International, 2009, 103, 302-306.	1.3	93
27	Lymphangiogenesis occurs in upper tract urothelial carcinoma and correlates with lymphatic tumour dissemination and poor prognosis. BJU International, 2009, 103, 1040-1046.	1.3	28
28	The role of lymphangiogenesis in lymphatic tumour spread of urological cancers. BJU International, 2009, 104, 592-597.	1.3	14
29	Evidence-based Sex-related Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results of Large Multicenter Study. Urology, 2009, 73, 142-146.	0.5	73
30	Assessment of the Minimum Number of Lymph Nodes Needed to Detect Lymph Node Invasion at Radical Nephroureterectomy in Patients With Upper Tract Urothelial Cancer. Urology, 2009, 74, 1070-1074.	0.5	58
31	Impact of Lymph Node Dissection on Cancer Specific Survival in Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy. Journal of Urology, 2009, 181, 2482-2489.	0.2	186
32	Prognostic Implications of Lymphangiogenesis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder. European Urology, 2008, 53, 571-580.	0.9	50
33	Lymphovascular Invasion and Pathologic Tumor Stage Are Significant Outcome Predictors for Patients With Upper Tract Urothelial Carcinoma. Urology, 2008, 72, 364-369.	0.5	33